Erdheim-Chester disease: a systematic review.

Area of Science:

• Histiocytosis Research
• Rare Diseases
• Genetics and Molecular Biology

Background:

• Erdheim-Chester disease (ECD) is a rare non-Langerhans-cell histiocytosis.
• BRAF(V600E) mutations are found in over 50% of ECD cases, originating from myeloid precursors or histiocytes.
• ECD exhibits a wide clinical spectrum, from asymptomatic bone lesions to life-threatening multisystemic disease.

Observation:

• A review of 448 histologically-confirmed ECD cases analyzed clinical, radiological, and therapeutic features.
• Central nervous system (CNS) involvement occurred in 56% of patients, manifesting as diabetes insipidus, visual disturbances, and neurological syndromes.
• Typical ECD presentation includes pituitary, retro-orbital, and axial lesions with osteosclerosis; CNS involvement correlates with decreased cardiac and increased other organ infiltration.

Findings:

• Patients with CNS infiltration showed a lower incidence of cardiac involvement.
• Conversely, CNS involvement was associated with a higher incidence of bone, skin, retro-peritoneal, lung, aortic, and renal infiltration.
• No significant differences in therapeutic approaches were observed when stratifying patients based on CNS involvement.

Implications:

• Understanding ECD pathogenesis, including BRAF deregulation, is crucial for developing improved prognostic criteria.
• Further research into ECD pathogenesis may lead to novel therapeutic strategies and better patient management.
• Identifying specific clinical signatures associated with CNS involvement can aid in risk stratification and personalized treatment planning.